Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
PaperCitations, authors & open-access status
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 319 citations, 2021 year and closed oa status.
319
Citations
2021
Year
closed
OA Status